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Abstract
Probiotic bacteria have a wide range of applications in veterinary and human therapeutics. Inactivated probiotics are
complex samples and quality control (QC) should measure as many molecular features as possible. Capillary electrophoresis
coupled to mass spectrometry (CE/MS) has been used as a multidimensional and high throughput method for the
identification and validation of biomarkers of disease in complex biological samples such as biofluids. In this study we
evaluate the suitability of CE/MS to measure the consistency of different lots of the probiotic formulation Pro-Symbioflor
which is a bacterial lysate of heat-inactivated Escherichia coli and Enterococcus faecalis. Over 5000 peptides were detected by
CE/MS in 5 different lots of the bacterial lysate and in a sample of culture medium. 71 to 75% of the total peptide content
was identical in all lots. This percentage increased to 87–89% when allowing the absence of a peptide in one of the 5
samples. These results, based on over 2000 peptides, suggest high similarity of the 5 different lots. Sequence analysis
identified peptides of both E. coli and E. faecalis and peptides originating from the culture medium, thus confirming the
presence of the strains in the formulation. Ontology analysis suggested that the majority of the peptides identified for E. coli
originated from the cell membrane or the fimbrium, while peptides identified for E. faecalis were enriched for peptides
originating from the cytoplasm. The bacterial lysate peptides as a whole are recognised as highly conserved molecular
patterns by the innate immune system as microbe associated molecular pattern (MAMP). Sequence analysis also identified
the presence of soybean, yeast and casein protein fragments that are part of the formulation of the culture medium. In
conclusion CE/MS seems an appropriate QC tool to analyze complex biological products such as inactivated probiotic
formulations and allows determining the similarity between lots.
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Introduction
Probiotic bacteria have a wide range of applications in
veterinary and human therapeutics [1–4]. The internationally
endorsed definition of probiotics determines probiotics as well-
defined micro-organisms that, when obtained in sufficient active
quantities in the gut, lead to positive effects on health (like
stabilising the gut microflora, reconstitution of the gut flora after
antibiotic therapy or having a protective effect against travellers
diarrhoe) [5,6]. Products with bacterial lysates contain heat-
inactivated probiotic bacteria. In that sense bacterial lysates are
not probiotics sensu stricto, but they are produced with probiotic
bacteria and can exhibit similar beneficial effects on the host as live
bacteria [7]. Most of the proven health effects probiotics elicit are
provided in the gastro-intestinal tract (GIT). Probiotics using live
bacteria maintain or promote the GIT homeostasis, and probiotics
have been found to stimulate the growth of indigenous beneficial
gut microbes such as bifidobacteria and inhibit the growth of
pathogenic or opportunistic pathogenic microbes [8–10]. In
addition, inactivated cells (heat or radiation induced) can also
improve the health of the host as shown in patients with irritable
bowel syndrome (IBS) [11]. In these patients administration of a
bacterial lysate of heat-inactivated Enterococcus faecalis (E. faecalis:
DSM16440) and Escherichia coli (E. coli: DSM17252), which was
identical to the bacterial lysate used in our study, significantly
improved IBS symptoms compared to placebo [11]. The
mechanisms of these inactivated bacteria on IBS are less clear,
but in vitro studies have shown that the beneficial effects might
originate from the anti-inflammatory properties of these inacti-
vated bacteria [7,12]. A number of bacterial lysates are
commercially available including Pro-Symbioflor containing an
E. faecalis and Escherichia coli lysate [11,13], Colibiogen containing
an E. coli lysate [14], CytoFloraH containing lysed cell walls of
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Bifidobacterium bifidum, Bifidobacterium infantis, Bifidobacterium longum,
Streptococcus thermophilus, Lactobacillus acidophilus, Lactobacillus rhamno-
sus, Lactobacillus plantarum, Lactobacillus salivarius, Lactobacillus reuteri,
Lactobacillus casei, Lactobacillus bulgaricus, and a species called
‘‘Lactobacillus sporogenes’’ (which is not an official species name)
[15] and Del-Immune VH containing cell wall peptidoglycans and
DNA fragments of Lactobacillus rhamnosus [16]. Besides for E. coli or
Enterococcus, in vitro studies are also available for Lactobacillus
rhamnosus or Streptococcus thermophilus to support the potential
beneficial effects on health [7,12]. Finally, the field of application
seems to have widened recently since bacterial lysates have been
shown as an alternative therapy of chronic obstructive pulmonary
disease (COPD) [17].
In rare cases probiotic bacteria can be isolated from human
clinical samples in nosocomial infections [18]. To be able to
identify those cases, the identity of the probiotic strain and its
characterisation by molecular methods must be provided by the
manufacturer. The concept of ‘‘Qualified Presumption of Safety’’
(QPS) as developed by the European Food Safety Authority
(EFSA) consequently requires the identification of probiotic
microorganism and also the identification of the organism in the
final product [19]. The requirements for quality control (QC) are
similar for probiotics with viable bacteria or bacterial lysates. In
Europe, this is regulated by European law and in the member
states enforced by national legislation (in Germany e.g. by
Arzneimittelgesetz, supervised by the national Federal Institute
for Drugs and Medicinal Devices) [20]. The difficulty associated
with maintaining a high degree of QC is inhibiting the
development of probiotic-based therapeutics.
Before bacterial cells of these lysates are autoclaved or
irradiated, regular quantitative and qualitative cultural and
genotypic QC methods are applied, as is required for viable
products [5]. These methods are not applicable for the final
product since no cultural methods can be applied and only
molecular methods are applicable. However, the complexity of
bacterial lysates is high and therefore QC of the lysates is best
performed with multidimensional techniques allowing the analysis
of a maximum of molecular features at one time. Indirect
techniques like proteomics are potentially suitable to describe the
molecular features in such complex samples. Proteomics, the
analysis of the total protein content of a sample, is a multidimen-
sional technique potentially able to grasp the complexity of
bacterial lysates. Proteomics has been used in a descriptive way to
determine the differences between a number of potential probiotic
bacterial isolates [21,22]. These studies provide comprehensive
catalogues and carry promise for the discovery of novel probiotic
effector molecules. However these techniques are labour intensive
and reproducibility, if not analysed in the same batch, is in general
low.
Capillary electrophoresis coupled to mass spectrometry (CE/
MS) is a high resolution and high throughput technology that has
been successfully applied for the discovery and validation of
peptide biomarkers of disease in biofluids [23]. CE/MS analysis
allows detecting thousands of peptides in a biofluid sample.
Furthermore, CE/MS has high reproducibility allowing the
comparison of the protein content of samples over time [24].
Therefore in the current study we evaluated the suitability of CE/
MS to serve as a high throughput technique for the QC analysis of
complex samples such as inactivated probiotics.
Materials and Methods
Bacterial strains
We used an autolysate of cells and cell fragments of E. faecalis
(DSM 16440) and E. coli (DSM 17252) called Pro-Symbioflor.
1.5 mL of Pro-Symbioflor contains 3.0 to 9.0 107 CFU of living
bacteria before inactivation. Rapidly after combining both strains
are exposed to heat and pressure (via autoclave), and the final
product is sterile thereafter.
Five Pro-Symbioflor lots were investigated in this study. The lots
were provided directly from the manufacturer (Symbiopharm
GmbH, Herborn, Germany) and stored according to the manufac-
turers instructions at room temperature until investigation. In
addition, for the comparison, a growth medium sample without
bacteria was also studied by CE/MS. The composition of this culture
medium is listed in Table 1. This growth medium is identical to the
medium used in commercial production of the product.
Sample preparation
For the analysis of the peptide content of bacterial lysates,
2.5 ml of Pro-Symbioflor was used. To decrease matrix effects by
removing electrolytes and salts, and also to enrich for polypeptides,
the samples were loaded onto PD-10 desalting column (GE
Healthcare, Sweden) equilibrated with 25 mL 0.01% NH4OH in
HPLC-grade H2O (Roth, Germany). Peptides were eluted by
adding 2.5 mL of 0.01% NH4OH. Finally, samples were
lyophilized and stored at 4uC. Shortly before CE-MS analysis,
lyophilized samples were resuspended in HPLC-grade H2O.
Capillary Electrophoresis-Mass Spectrometry (CE/MS)
analysis
CE/MS analysis was performed as previously described using a P/
ACE MDQ capillary electrophoresis system (Beckman Coulter,
Fullerton, USA) on-line coupled to a MicroTOF MS (Bruker Daltonic,
Bremen, Germany) [25]. The ESI sprayer (Agilent Technologies, Palo
Alto, USA) was grounded, and the ion spray interface potential was set
between 24.0 and 24.5 kV. Data acquisition and MS acquisition
methods were automatically controlled by the CE via contact-close-
relays. Spectra were accumulated every 3 s over a range of m/z 350 to
3000. Details on accuracy, precision, selectivity, sensitivity, reproduc-
ibility, and stability of the CE-MS method have been provided
previously [24,26].
Table 1. Composition of culture medium.
medium composition concentration (mg/ml)
lactose monohydrate 4.9000
sodium carbonate decahydrate 0.9600
sodium chloride 3.8000
magnesium sulfate heptahydrate 0.7790
potassium chloride 0.1330
calcium chloride dihydrate 0.0760
magnesium chloride hexahydrate 0.6080
standard nutrient broth 0.020 ml consisting of:
casein peptone (soybean) 0.300
yeast extract 0.060
sodium chloride 0.120
glucose monohydrate 0.020
doi:10.1371/journal.pone.0066682.t001
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Data processing
Mass spectral ion peaks representing identical molecules at
different charge states were deconvoluted into single masses using
MosaiquesVisu software [27]. Only those signals with z.1 that
were observed in a minimum of 2 consecutive spectra with signal-
to-noise ratios .4 were included. The software employs a
probabilistic clustering algorithm and uses both isotopic distribu-
tion as well as conjugated masses for charge-state determination of
peptides/proteins. The resulting peak list characterizes each
polypeptide by its molecular mass, CE-migration time, and ion
signal intensity (amplitude) value. To minimize effects of biological
and analytical variability between the different lots a normaliza-
tion of retention time, signal intensity and mass was performed.
The CE migration time was normalized by local regression using
281 references between 17 and 46 Minutes. The masses were
calibrated utilizing 274 reference masses in the range of 800–
3000 Da by applying linear regression. Normalization of signal
intensities was based on 43 ‘‘internal standard’’ peptides detected
in all 5 lots with relative low cV, similarly to what has been
described for urinary peptidome analysis [28]. Here linear
regression was applied as well.
All detected peptides were deposited, matched, and annotated
in a Microsoft SQL database, allowing further analysis and
comparison of multiple samples [29]. Peptides were considered
identical within different samples, when mass deviation was lower
than 50 ppm for small peptides or 75 ppm for larger peptides and
proteins. Due to analyte diffusion, CE peak widths increase with
CE migration time. In the data clustering process this effect was
compensated by linearly increasing cluster widths over the entire
measurement from 2 to 5%.
Peptide sequencing
Bacterial lysates were separated on a Dionex Ultimate 3000
RSLS nano flow system (Dionex, Camberly UK). A 5 ml sample
was loaded in 0.1% formic acid and acetonitrile (98:2) onto a
Dionex 100 mm32 cm, 5 mm C18 nano trap column at a flowrate
of 5 ml/min. Elution was performed on an Acclaim PepMap C18
nano column 75 mm315 cm, 2 mm, 100 A˚ with a linear gradient
of 0.1% formic acid against 100% acetonitrile starting at 5%–50%
over 100 min. The sample was ionised in positive ion mode using
a Proxeon nano spray ESI source (Thermo Fisher Hemel UK) and
analysed in an Orbitrap Velos FTMS (Thermo Finnigan, Bremen,
Germany). The MS was operated in data-dependent mode to
switch between MS and MS/MS acquisition and parent ions were
fragmented by high-energy collision-induced dissociation. Data
files were searched against E. coli, E. faecalis, Bos Taurus, Yeast and
Figure 1. Peptide content of bacterial lysates and medium. Contourplots showing all polypeptides detected in the 5 lots of Pro-SymbioFlor
and culture medium, displayed in three dimensions (x-axis: migration time in Minutes, y-axis: mass in logarithmic scale and Da, peak height (z-axis):
signal intensity).
doi:10.1371/journal.pone.0066682.g001
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Soyabean entries in the Swiss-Prot database without any enzyme
specificity using Open Mass Spectrometry Search Algorithm
(OMSSA, http://pubchem.ncbi.nlm.nih.gov/omssa) with an e-
value cut-off of 0.1. No fixed modification and oxidation of
methionine as variable modifications were selected. Mass error
windows of 10 ppm and 0.05 Da were allowed for MS and MS/
MS, respectively. For further validation of obtained peptide
identifications, the strict correlation between peptide charge at
pH 2 and CE-migration time was utilized to minimize false-
positive identification rates [30]. Calculated CE-migration time of
the sequence candidate based on its peptide sequence (number of
basic amino acids) was compared to the experimental migration
time. Peptides were accepted only if they had a mass deviation
below 680 ppm and a CE-migration time deviations below
62 min.
Figure 2. Similarity of different lots based on peptide content. Graphical representation of the presence of identical peptides. A) Shown is
the absolute number of detected peptides in the 5 different Pro-Symbioflor lots and in the culture medium and B) peptide abundance based on
relative ion counts of each lot.
doi:10.1371/journal.pone.0066682.g002
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Results
Comparison of the different bacterial lysate preparations
Five different lots of the bacterial lysates (lot 0454/10, 0455/2,
0456/2, 0457/10, 0458/2) as well as the culture medium were
analyzed by CE/MS. A total of 5217 different peptides could be
detected in all lots (Figure 1). Each peak in the contourplots
represents a peptide that is tagged by a unique identifier consisting
of a mass and migration time. The height of each peak indicates
the abundance of the different peptides.
Table 2. Percentage of identical peptides present in a lot (expressed as the percentage of the total signal intensity in the lot)
compared to the other lots.
Lot ID 0454/10 0455/2 0456/2 0457/10 0458/2 Culture medium Total PPs*
all 5 lots 72% (84%) 75% (84%) 73% (88%) 71% (83%) 73% (88%) 51% (68%) 1391
4 of 5 lots 15% (12%) 15% (12%) 15% (9%) 15% (11%) 15% (9%) 12% (16%) 894
3 of 5 lots 7% (2%) 5% (2%) 5% (2%) 7% (3%) 5% (3%) 11% (7%) 804
2 of 5 lots 3% (1%) 3% (2%) 4% (1%) 5% (1%) 5% (1%) 8% (4%) 873
1 of 5 lots 2% (1%) 2% (0%) 3% (0%) 1% (0%) 2% (0%) 5% (4%) 1255
only in culture
medium
0% (0%) 0% (0%) 0% (0%) 0% (0%) 0% (0%) 14% (1%) 132
The percentage of sequenced peptides (expressed as the percentage of the total signal intensity) is given between brackets. *PPs, polypeptides.
doi:10.1371/journal.pone.0066682.t002
Figure 3. Expression profiles of sequenced bacterial peptides. Contourplots of the sequenced polypeptides originating from E. coli and E.
faecalis in the 5 lots of Pro-Symbioflor and culture medium. To improve visualization of the peptides in this contourplot, the abundance of the
peptides was artificially amplified with a factor 3 in relation to Figure 1. The 9 signals shown in culture medium are false positive hits by sequencing
via LC-MS/MS. Given that 390 bacterial peptides were identified we obtained an acceptable false discovery rate of below 5%.
doi:10.1371/journal.pone.0066682.g003
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As all five lots are derived from the same set of strains and were
produced under identical conditions, similarity between the data
in the 5 samples should be high, and distinctly different from the
data obtained when analyzing medium only. The overall similarity
of the 5 samples and the difference with medium only can be
clearly observed by visual inspection of the contourplots
(Figure 1). The similarity is also observed when analyzing the
number and abundance of detected peptides in the different lots.
In the bacterial lysates 2939 to 3381 different peptides were
detected, while approximately 3 times less different peptides (964)
were detected in culture medium (Figure 2 A). 132 peptides were
exclusively detected in culture medium suggesting transformation
of these peptides by the bacteria. When looking at the relative
abundance of the peptides, the similarity between the lots is
striking as well. The abundance of peptides detected in all 5 lots
(1391 peptides) represent 71–75% of the total content (based on
ion counting) (Table 2 and Figure 2 B). If the absence of a single
peptide in one of the 5 lots is accepted, an additional 894 peptides
are present in four of the five lots. These peptides represent a total
of 87–89% of all observed peptides, which suggests high
consistency in all samples. Peptides which occur only sporadically
(in one or two lots) represent only 5–7% of the total polypeptide
content.
Overall these data show, using a technique that allows grasping
thousands of molecular features in a routine manner, high
similarity of the 5 different lots.
Sequencing of bacterial lysate peptides
To obtain additional information on the observed peptides and
link the peptides to the different bacterial strains or to medium and
potentially lay the groundwork for the identification of specific
probiotic peptides, MS/MS sequencing was performed. The
search for E. coli and E. faecalis entries in the lots resulted in
identification of 517 peptides originating from E. faecalis and 406
originating from E. coli. These sequences (E. coli and E. faecalis)
were matched to the CE/MS data profiles and resulted in
identification of amino acid sequence of 390 CE/MS-detected
peptides (Table S1 and Figure 3). Ontology-based analysis of
these 390 peptides showed that the majority of the identified
cellular components identified for E. coli originated from the cell
membrane and the fimbrium (Figure 4). In contrast, the major
cellular components identified for E. faecalis originated from the
cytoplasm. However, definition of the peptide-content based on
molecular function showed in both strains enrichment for
hydrolases and transferases. Processes involving DNA (i.e.
Figure 4. Ontology based characterization of the peptides identified by CE/MS. Based on the Uniprot identifiers the involvement of a
protein (defined by one or more CE/MS peptides) in a biological process, molecular function and cellular component was determined. The pie-charts
show the percentage of proteins in each group. Only classes represented by 4 or more proteins are shown. Classes for which we identified less than 4
proteins are indicated and grouped as ‘‘others’’. A) Classification for E. coli and B) classification for E. faecalis.
doi:10.1371/journal.pone.0066682.g004
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damage, integration, recombination etc…) were the top class when
considering biological processes in both strains.
In culture medium 933 different yeast, 199 casein and 88
fragments from soybean could be identified in the MS/MS
experiments confirming the composition of the culture medium
(Table 1). Matching of the sequenced peptides of the medium to
CE/MS detected peptides led to the identification of 175 CE/MS
detected peptides (Table S1 and Figure 5).
Discussion
Quality control of inactivated bacterial lysates has concentrated
on the control of the functional characteristics, like the quantifi-
cation of expressed genes [31]. So far no targeted QC procedures
concerning the identity of the strains for bacterial lysates are
available after inactivation. Especially no cultural methods can be
applied for classical identification and quantification. Only
molecular methods are applicable. However, the complexity of
bacterial lysates is high and therefore QC of the lysates is best
performed with multidimensional techniques allowing the analysis
of a maximum of molecular features at one time. CE/MS has
been largely used for the definition of diagnostic and prognostic
biofluid biomarkers of different diseases [23,29,32–35] and has
been shown to be highly reproducible with a short turnaround
time [24]. For this reason we decided to study whether CE/MS
could be used for QC control of probiotic bacterial lysates. For
QC in CE/MS analysis for clinical use, we 1) developed standard
operating procedures for reproducible sample preparation [36]; 2)
developed specific software solutions for efficient and reproducible
data processing [37] and 3) identified internal calibrants that
enable comparison of the datasets [28]. These quality control steps
were applied to the bacterial lysates in the current study to
minimize the variability and to achieve high reproducibility and
can be used in future studies. Using CE/MS we showed high
similarity between 5 different lots of the Pro-Symbioflor formu-
lation on the peptidome level and identified, using peptide
sequence analysis, the presence of proteins typical for the two
strains included in the formulation. Clear differences between the
peptide content of the Pro-Symbioflor formulation and the
medium used for cultivation of the bacteria could also be observed.
The CE/MS approach provides evidence for Pro-Symbioflor
lot similarity and content on several levels. On the total peptide
level, including peptides with known and unknown sequence and
where peptides are annotated with a unique tag comprised of mass
and CE migration time, a pool of .5000 peptides can be used to
obtain a peptide profile. Based on these peptide profiles, consisting
Figure 5. Expression profiles of peptides originating from the medium. Contourplots of the sequenced polypeptides originating from the
culture medium only. To improve visualization of the peptides in this contourplot, the abundance of the peptides was artificially amplified with a
factor 3 in relation to figure 1.
doi:10.1371/journal.pone.0066682.g005
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of 2000–3000 peptides per lot, high similarity between the lots
could be determined (Table 2). Sequence information of the
peptides allows clear cut identification of the species present in the
sample. The sequenced peptides clearly showed the presence of
fragments of the two bacterial strains with comparable ratios
between the different strains in the different lots.
Ontology analysis showed that the majority of the CE/MS-
detected peptides of E. coli were identified as cell wall components
which might have a role in activating the innate immune system,
as has been shown for Staphylococcus aureus [38]. Parts of the cell
wall of bacteria have also been successfully applied in atopic
dermatitis [39]. These bacterial lysate peptides as a whole are
recognised as highly conserved molecular patterns by the innate
immune system as microbe associated molecular pattern (MAMP)
[39,40].
Upon matching of the sequenced peptides to the CE/MS
peptides, nine sequences originating from either E. coli or E. faecalis
were also found in the medium sample (see Figure 3). pBLAST
analysis showed that all 9 peptides belonged with 100% homology
to the bacterial sequences. Therefore, these 9 sequences were most
likely not correctly matched to the CE/MS-detected peptides
within the allowed mass and migration time deviation. This
suggests that for a reduced number of peptides (2.3%), the
resolution of CE/MS is not high enough to differentiate between
two peptides with very close mass and CE migration time.
Sequence analysis identified with high confidence the presence
of 88 peptide sequences that were fragments of soybean proteins
(OMSSA Search, Table 1). This shows the ability of the CE/MS-
based analysis to identify even hydrolysates in complex samples
such as bacterial lysates.
Finally, CE/MS based detection of peptides originating from
the medium also gives information on the QC for the medium
used for cultivation of the probiotic bacteria. Our method
therefore seems suitable to be used as a QC tool for both quantity
and quality in complex samples to comply with safety rules for
probiotics as required e.g. by EFSA through the QPS system [19].
Although, CE/MS has been extensively used for the discovery
and validation of disease in biofluids this is, to our knowledge, the
first study showing the suitability of CE/MS in quality control of
complex probiotic formulations. CE/MS has been proposed in the
QC of biopharmaceuticals (e.g. production of recombinant human
interferon-b [41], detection of enantiomeric impurities (CE-MS/
MS) [42], purity of drugs such as carbachol, lidocaine and
proguanil [43], cosmetic [44]) or even at traditional Chinese
medicines [45], but never for highly complex formulations such as
inactivated probiotics [46].
In conclusion, our studies on Pro-Symbioflor lysate suggest that
CE/MS is a well suited tool for the QC of inactivated probiotics.
Supporting Information
Table S1 CE/MS Analysis of lots. All detected peptides using
CE/MS are listed. Additionally shown are matched MS/MS hits
of peptides. From left to right: Internal peptide ID, mass in Dalton,
CE migration time in minutes, signal intensity of culture medium
sample, organism, amino acid sequence, description of mother-
protein, accession number (uniprot), start and stop of sequence,
intensity of lots, frequency of found peptides, mean intensity of 5
lots, standard deviation, coefficient of variation in%, sequencing
information for peptides originated from bacteria: organism,
amino acid sequence, protein name, accession number (uniprot)
and start and stop of sequence.
(XLSX)
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